In preclinical studies, A2AR antagonists showed potential benefits in the treatment of some neurodegenerative diseases like Alzheimer’s disease (AD) and Parkinson’s disease (PD), neuroinflammation, ischemia, spinal cord injury, drug addiction and other conditions [31]. Here, ADORA2A is linked to Alzheimer disease.